Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04916548 · ClinicalTrials.gov registry record · Phase 1
Repeated Neurocognitive Measurements in Depressed Patients
A Phase 1 study, sponsored by Rebecca Price.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT04916548 is a Phase 1 study that has completed, run by Rebecca Price. The registered enrollment target is 15 participants.
The verdict
NCT04916548, a Phase 1 study, has completed, sponsored by Rebecca Price.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
In this project, we will A) track the functioning of a collection of potential neurobiological targets for depression over time, B) examine how fluctuations in the functioning of those targets relates to real-world functioning, and C) in a subset of the sample, determine how the functioning in those targets is altered by a single dose of ketamine.
Interventions
- DRUG Intravenous Ketamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2021-09-16 |
| Est. Completion | 2023-08-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04916548
The ClinicalTrials.gov registry entry for NCT04916548 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rebecca Price, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Intravenous Ketamine is the first listed.
NCT04916548 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04916548 about?
NCT04916548 is a clinical study titled "Repeated Neurocognitive Measurements in Depressed Patients". In this project, we will A) track the functioning of a collection of potential neurobiological targets for depression over time, B) examine how fluctuations in the functioning of those targets relates to real-world functioning, and C) in a subset of the sample, determine how the functioning in those...
What is the current status of trial NCT04916548?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2021-09-16. Estimated completion is 2023-08-15.
What interventions are being tested in trial NCT04916548?
The interventions under investigation include: Intravenous Ketamine (DRUG).
Who is sponsoring clinical trial NCT04916548?
This trial is sponsored by Rebecca Price, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.